Trial · NCT02463799
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Immune Responses to Treatment With Sipuleucel-T (With or Without Radium-223) Measured by Peripheral PA2024 T-cell Proliferation | 6 weeks | fold change | MEDIAN | |
| SECONDARY | Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Up to 52 weeks | Data was only collected from 13 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 10 out of 16 participants in the Sipuleucel-T arm | Stimulation Index | MEAN |
| SECONDARY | Time to Radiographic or Clinical Progression | Up to 2 years | WEEKS | MEDIAN | |
| SECONDARY | PSA50 Response (at Least a 50% Decline in PSA) | Up to 2 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Peripheral PAP Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Up to 52 weeks | Data was only collected from 13 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 10 out of 16 participants in the Sipuleucel-T arm | Stimulation Index | MEAN |
| SECONDARY | Peripheral PA2024 Specific T-cell Activation | Up to 52 weeks | Data was only collected from 13 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 10 out of 16 participants in the Sipuleucel-T arm | cells per 300,000 PBMCs | MEAN |
| SECONDARY | Peripheral PAP Specific T-cell Activation | Up to 52 weeks | Data was only collected from 13 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 10 out of 16 participants in the Sipuleucel-T arm | cells per 300,000 PBMCs | MEAN |
| SECONDARY | PA2024 Specific Antibody (IgM) Response | Up to 52 weeks | Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm | titer | MEAN |
| SECONDARY | PA2024 Specific Antibody (IgG) Response | Up to 52 weeks | Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm | titer | MEAN |
| SECONDARY | PAP Specific Antibody (IgG) Response Over Time | Up to 52 weeks | Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm | titer | MEAN |
| SECONDARY | PAP Specific Antibody (IgM) Response | Up to 52 weeks | Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm | titer | MEAN |
| SECONDARY | Sipuleucel-T Product Immune Parameters as Assessed by Number of CD54+ Cells | Up to 4 weeks | Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm | cells x 10 ^ 6 | MEAN |
| SECONDARY | Sipuleucel-T Product Immune Parameters as Assessed by CD54+ Upregulation | Up to 4 weeks | Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm | cells x 10^6 | MEAN |
| SECONDARY | Sipuleucel-T Product Immune Parameters as Assessed by Total Nucleated Cell Count | Up to 4 weeks | Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm | cells 10^6 | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02463799/outcomes